title: [Liver function tests, hepatitis A, B, C markers and HIV antibodies in patients with Basedow's ophthalmopathy treated with intravenous immunoglobulins].
abstract: Recent reports of transmission by intravenous gamma-globulin preparations of A, B, C and non-A non-B hepatitis (NANBH), including several cases that progressed to severe liver damage and death, have raised concerns about the safety of intravenous gamma-globulins. To assess this issue 15 patients treated with high-dose "intravenous immunoglobulin" (IVIG) for Graves' Ophthalmopathy had serial determination of glutamic pyruvic transaminase (GPT), glutamic oxalacetic transaminase (GOT), gamma glutamyltranspeptidase (gamma-GT), alkaline phosphatase and bilirubin that were performed regularly at interval of 3 weeks during IVIG treatment and 6 months after the end of the treatment. Hepatitis A, B, C and HIV markers were determined before, during and 6 months after the end of the treatment. The standard dosage was 400 mg per Kg body weight IVIG (3 cycles of 5 days and 12 of 1 day, every 21 days). Transient minor elevations were observed for GPT, for GOT, for gamma-GT and alkaline phosphatase. None of the elevations were considered indicative of NANBH or of any chronic hepatic disease. Transient presence of hepatitis A, B and C antibodies were observed in 6 patients. All patients remained negative for hepatitis B antigens throughout the study. HIV antibodies resulted always negative in all patients. In conclusion this study suggests the hepatitis and HIV safety of IVIG.
authors: Clinica Medica II, Università degli Studi di Pisa.
authors: A
authors: A
authors: Antonelli
authors: S
authors: S
authors: Neri
authors: L
authors: L
authors: Gasperini
authors: B
authors: B
authors: Alberti
authors: A
authors: A
authors: Saracino
authors: C
authors: C
authors: Gambuzza
authors: S
authors: S
authors: Agostini
authors: L
authors: L
authors: Baschieri
mesh_terms: D006111:Graves Disease / Q000628:therapy*; D015483:HIV Antibodies / Q000097:blood*; D006506:Hepatitis A / Q000209:etiology; D006509:Hepatitis B / Q000209:etiology; D006526:Hepatitis C / Q000209:etiology; D006525:Hepatitis, Viral, Human / Q000175:diagnosis / Q000209:etiology*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects* / Q000627:therapeutic use; D008111:Liver Function Tests; D011446:Prospective Studies; D012698:Serologic Tests
chemical_list: D015483:HIV Antibodies; D016756:Immunoglobulins, Intravenous
vernacular_title: Monitoraggio delle prove di funzione epatica, dei markers dell'epatite A, B, C e degli anticorpi anti HIV nei pazienti trattati con immunoglobuline endovena (IVIG) per oftalmopatia basedowiana.